Sangamo Therapeutics/ US8006771062 /
2024-04-22 9:59:55 PM | Chg. 0.00 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
0.52USD | +0.16% | 41,263 Turnover: 20,925.81 |
-Bid Size: - | -Ask Size: - | 0.53 | 0.48 |
GlobeNewswire
04-22
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...
GlobeNewswire
04-16
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...
GlobeNewswire
03-26
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-26
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Atax...
GlobeNewswire
02-20
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for A...
GlobeNewswire
01-03
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-02
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
2023-12-06
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Scler...
GlobeNewswire
2023-11-06
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
GlobeNewswire
2023-10-30
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
GlobeNewswire
2023-09-25
Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
GlobeNewswire
2023-09-07
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2023-08-21
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
GlobeNewswire
2022-01-20
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors